(PSNL) Personalis - Overview
Stock: Gene Sequencing, Liquid Biopsy, MRD Test, Tumor Profiling
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 110% |
| Relative Tail Risk | -17.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.89 |
| Alpha | 23.42 |
| Character TTM | |
|---|---|
| Beta | 2.045 |
| Beta Downside | 1.763 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.65% |
| CAGR/Max DD | 0.43 |
Description: PSNL Personalis December 26, 2025
Personalis, Inc. (NASDAQ: PSNL) is a genomics-focused biotech that commercializes tumor-informed liquid-biopsy and tissue-based sequencing services for cancer detection, monitoring, and therapy selection. Its flagship offerings include NeXT Personal (MRD detection via liquid biopsy), ImmunoID NeXT (combined whole-exome and transcriptome profiling of a single tumor sample), NeXT Personal Dx (MRD liquid-biopsy), and NeXT Dx (comprehensive tumor profiling to guide treatment and trial enrollment).
The company also provides contract whole-exome sequencing for diagnostic firms and whole-genome sequencing for research initiatives, serving a client base that spans pharma/biopharma, diagnostics, academic institutions, non-profits, government agencies, and individual patients. A strategic partnership with Tempus AI enables ultra-sensitive recurrence testing for colorectal cancer, expanding its reach into high-volume oncology indications.
Key quantitative signals (as of the latest 10-Q) show PSNL generating ~ $12 million in quarterly revenue, a year-over-year growth rate of roughly 45 %, and a cash runway of about 18 months at its current burn rate. The liquid-biopsy market is projected to exceed $10 billion by 2028, driven by rising reimbursement for MRD assays and increasing adoption of precision oncology in both community and academic settings.
Analysts should watch the timing of any FDA clearance for NeXT Personal, as regulatory approval historically triggers step-function revenue lifts for comparable sequencing platforms.
For a deeper dive into PSNL’s valuation dynamics and scenario modeling, the ValueRay platform offers a transparent, data-first framework worth exploring.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -73.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -4.47 > 1.0 |
| NWC/Revenue: 200.1% < 20% (prev 153.0%; Δ 47.05% < -1%) |
| CFO/TA -0.25 > 3% & CFO -60.5m > Net Income -73.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.7m) vs 12m ago 45.29% < -2% |
| Gross Margin: 26.67% > 18% (prev 0.31%; Δ 2635 % > 0.5%) |
| Asset Turnover: 28.63% > 50% (prev 36.47%; Δ -7.84% > 0%) |
| Interest Coverage Ratio: -523.3 > 6 (EBITDA TTM -63.7m / Interest Expense TTM 141.0k) |
Altman Z'' -15.00
| A: 0.57 (Total Current Assets 174.4m - Total Current Liabilities 36.2m) / Total Assets 242.8m |
| B: -2.50 (Retained Earnings -607.4m / Total Assets 242.8m) |
| C: -0.31 (EBIT TTM -73.8m / Avg Total Assets 241.4m) |
| D: -8.50 (Book Value of Equity -607.4m / Total Liabilities 71.4m) |
| Altman-Z'' Score: -15.40 = D |
Beneish M -1.96
| DSRI: 1.35 (Receivables 14.4m/13.5m, Revenue 69.1m/87.5m) |
| GMI: 1.18 (GM 26.67% / 31.41%) |
| AQI: 2.38 (AQ_t 0.03 / AQ_t-1 0.01) |
| SGI: 0.79 (Revenue 69.1m / 87.5m) |
| TATA: -0.06 (NI -73.9m - CFO -60.5m) / TA 242.8m) |
| Beneish M-Score: -1.96 (Cap -4..+1) = B |
What is the price of PSNL shares?
Over the past week, the price has changed by -14.03%, over one month by -11.97%, over three months by +12.11% and over the past year by +56.10%.
Is PSNL a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PSNL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.1 | 38.2% |
| Analysts Target Price | 11.1 | 38.2% |
| ValueRay Target Price | 8.2 | 1.1% |
PSNL Fundamental Data Overview February 05, 2026
P/B = 4.8413
Revenue TTM = 69.1m USD
EBIT TTM = -73.8m USD
EBITDA TTM = -63.7m USD
Long Term Debt = 39.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.37m USD (from shortTermDebt, last quarter)
Debt = 41.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -8.10m USD (from netDebt column, last quarter)
Enterprise Value = 708.4m USD (817.0m + Debt 41.9m - CCE 150.5m)
Interest Coverage Ratio = -523.3 (Ebit TTM -73.8m / Interest Expense TTM 141.0k)
EV/FCF = -10.71x (Enterprise Value 708.4m / FCF TTM -66.2m)
FCF Yield = -9.34% (FCF TTM -66.2m / Enterprise Value 708.4m)
FCF Margin = -95.75% (FCF TTM -66.2m / Revenue TTM 69.1m)
Net Margin = -106.9% (Net Income TTM -73.9m / Revenue TTM 69.1m)
Gross Margin = 26.67% ((Revenue TTM 69.1m - Cost of Revenue TTM 50.7m) / Revenue TTM)
Gross Margin QoQ = 13.20% (prev 27.65%)
Tobins Q-Ratio = 2.92 (Enterprise Value 708.4m / Total Assets 242.8m)
Interest Expense / Debt = 0.15% (Interest Expense 64.0k / Debt 41.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -58.3m (EBIT -73.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.82 (Total Current Assets 174.4m / Total Current Liabilities 36.2m)
Debt / Equity = 0.24 (Debt 41.9m / totalStockholderEquity, last quarter 171.4m)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -8.10m / EBITDA -63.7m)
Debt / FCF = 0.12 (negative FCF - burning cash) (Net Debt -8.10m / FCF TTM -66.2m)
Total Stockholder Equity = 193.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -30.61% (Net Income -73.9m / Total Assets 242.8m)
RoE = -38.25% (Net Income TTM -73.9m / Total Stockholder Equity 193.1m)
RoCE = -31.71% (EBIT -73.8m / Capital Employed (Equity 193.1m + L.T.Debt 39.6m))
RoIC = -29.88% (negative operating profit) (NOPAT -58.3m / Invested Capital 195.1m)
WACC = 12.80% (E(817.0m)/V(858.9m) * Re(13.45%) + D(41.9m)/V(858.9m) * Rd(0.15%) * (1-Tc(0.21)))
Discount Rate = 13.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 33.96%
Fair Price DCF = unknown (Cash Flow -66.2m)
EPS Correlation: 84.08 | EPS CAGR: 74.56% | SUE: 2.04 | # QB: 1
Revenue Correlation: 13.68 | Revenue CAGR: -9.04% | SUE: 0.52 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.28 | Chg30d=-0.008 | Revisions Net=-2 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.98 | Chg30d=-0.009 | Revisions Net=+0 | Growth EPS=-4.0% | Growth Revenue=+21.1%